| Type of Vaccine | Composition / Adjuvant | Via | Phase of Study | Patients | Immune Response | Clinical Response | Refs. |
|---|---|---|---|---|---|---|---|
| Peptide vaccines | HPV-16 E786-93 peptide conjugated with lipid (palmitic acid) linked to the non-specific PADRE helper peptide ADDIN EN.CITE ADDIN EN.CITE.DATA [65, 66] | SC | I | 12 patients (HLA-A*0201) with refractory cervical or vaginal cancer | E7-specific CTL response in 7 patients | No clinical response | a |
| Two HPV-16 E7 peptides (E712-20 and E786-93) linked to the non-specific PADRE helper peptide Adjuvant: IFA | SC | I-II | 19 cervical cancer patients (HLA-A*0201) | No E7-specific CTL response | 2 partial remissions | b | |
| E712-20 and E786-93 Peptides linked to the PADRE helper peptide bound to a lipid radicalAdjuvant : IFA | SC | I | 18 patients (HLA-A*0201) with high-grade cervical or vulvar intraepithelial neoplasia | E7-specific CTL response in 10 patients | 3 complete remissions9 partial remissions | c | |
| Protein vaccines | Fusion protein containing HPV-16 E7 and HSP-65 ofMycobacterium Bovis BCG | SC | II | 22 anal HSIL patients, of which 14 presented anogenital condiloma | Non-determined | 3 complete remissions10 partial remissions | d |
| Fusion protein containing HPV-16 L2, E6 and E7(TA-CIN) | IM | I | 40 healthy volunteers | E6 and E7-specific CTL responses in 8 patients | Not determined | e | |
| Three doses ofTA-CIN, followed by one dose of TA-HPV (see below Viral Vector Vaccines)(Prime-boost trial) | IM | II | 29 | ||||
| Fusion protein containing HPV-16 E6 and E7 Adjuvant: ISCOMATRIX® ADDIN EN.CITE ADDIN EN.CITE.DATA | IM | I | 8 CIN I patients10 CIN II patients NIC II13 CIN III patients | Specific CTL responses in 5 patientsDelayed type hypersensitivity (DTH)To E6 and E7 in 18 patients | 4 complete remissions | f | |
| Fusion protein containing an HPV-16 E7 mutant conjugated to the Haemophilus influenzae protein D (PD-E7)Adjuvant : AS02B | IM | I/II | 5 CIN III patients2 CIN I patients | Increase of preexisting cellular response to PD-E7 in 5 patients | 2 remissions(CIN I patients) | g | |
| Dendritic cell vaccines | Autologous DCs loaded with recombinant HPV-16 or HPV-18 E7 protein | SC | I | 15 grade IV cervical cancer patients | CTL responses in 4 patientsAntibody responses in 3 patients | No | h |
| DCs loaded with HPV-16 E7 or HPV-18and human recombinant IL-2 | SC | I | 4 cervical cancer patients (HPV-16+ or HPV-18+) refractory to standard treatment | Specific antibody and CD4+ T lymphocytes in 2 patientsIncrease in E7-specific CD8+ T cellsin 4 patients | No | i | |
| DNA vaccines | ZYC101: Zycos 101 plasmid DNA encoding several HLA-A2 epítopes from HPV-16 E7 Encapsulated in microparticles of biodegradable polymer | IM | I | 12 anal dysplasia patients | Increasedresponses to E7 epitopes in10 cases | 3 partial remissions | j |
| ZYC101 | SC / IM | I | 15 CIN II/III patients | 11 HPV-specific CTL responses | 5 complete remissions | k | |
| Amolimogene/ZYC101a: plasmid DNA encoding fragments from HPV-16 and 18 E6 and E7Encapsulated in microparticles of biopolymer | IM | II | 127 CIN II/III patients(86 under treatment) | 80 Increased preexisting specific T cell responses | 37 complete remissions | l | |
| Viral vector vaccines | TA-HPV vaccine: vaccinia virus strain Wyeth encoding a HPV 16 and 18 E6/ E7 fusion protein | Dermal scarification | I | 8 advanced cervical cancer patients (grades Ib-IIIb or recurrent) | 3 humoral responses against E6/E7, and 8 anti-vaccinia1 HPV-specific CTL response | No | m |
| TA-HPV | Dermal scarification | I | 29 cervical cancer patients (grade Ib o IIa) | 8 HPV-specific antibody responses4 HPV-specific CTL responses | No | n | |
| TA-HPV | Dermal scarification | II | 12 VIN patients | 6 CD4+ T lymphocyte responses10 HPV-specific antibody responses | 5 partial remissions1 complete remission | o | |
| TA-HPV | Dermal scarification | II | 18 high grade VIN patients | 8 T cell proliferation responses5 INF-g response1 humoral response | 8 partial remissions | p | |
| MVA-E2 | Intra- uterus | I-II | 36 CIN I, II or III patients | Humoral and cellular responses in all cases | 34 complete remissions | q | |
| MVA-E2 | Intra-uterus | II | 34 CIN II or III patients | Humoral and cellular responses in all cases | 20 complete remissions11 partial remissions | r | |
| MVA-HPV-IL2: recombinant Modified Vaccinia Virus Ankara (MVA), attenuated vaccinia strain, encoding modified E6 y E7 proteins and IL-2 | IM | II | 31 CIN II/III patients | Not reported | 5 partial remissions | s | |
| MVA-HPV-IL2 | SC | II | 21 CIN II/III patients | Not reported | 10 partial remissions | t |